Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Market Cap $1.045B
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Announcements
Filter Results
| NAN | Change of Director's Interest Notice | 12/04/18 | ||
| NAN | New German guidelines for probe decontamination | 05/04/18 | ||
| NAN | Ceasing to be a substantial holder from MQG | 04/04/18 | ||
| NAN | Becoming a substantial holder from MQG | 29/03/18 | ||
| NAN | Change of Director's Interest Notice | 21/03/18 | ||
| NAN | Appendix 3B | 13/03/18 | ||
| NAN | Change in substantial holding | 12/03/18 | ||
| NAN | Change in substantial holding | 12/03/18 | ||
| NAN | Change of Director's Interest Notice | 12/03/18 | ||
| NAN | Change of Director's Interest Notice - Correction | 07/03/18 | ||
| NAN | Change of Director's Interest Notice | 06/03/18 | ||
| NAN | Change of Director's Interest Notice | 06/03/18 | ||
| NAN | Appendix 3B | 06/03/18 | ||
| NAN | 2018 Half Year Results Investor Presentation | PRICE SENSITIVE | 26/02/18 | |
| NAN | Appendix 4D and Half Year Report | PRICE SENSITIVE | 23/02/18 | |
| NAN Change of Director's Interest Notice | |||
| 12/04/18 | |||
| NAN New German guidelines for probe decontamination | |||
| 05/04/18 | |||
| NAN Ceasing to be a substantial holder from MQG | |||
| 04/04/18 | |||
| NAN Becoming a substantial holder from MQG | |||
| 29/03/18 | |||
| NAN Change of Director's Interest Notice | |||
| 21/03/18 | |||
| NAN Appendix 3B | |||
| 13/03/18 | |||
| NAN Change in substantial holding | |||
| 12/03/18 | |||
| NAN Change in substantial holding | |||
| 12/03/18 | |||
| NAN Change of Director's Interest Notice | |||
| 12/03/18 | |||
| NAN Change of Director's Interest Notice - Correction | |||
| 07/03/18 | |||
| NAN Change of Director's Interest Notice | |||
| 06/03/18 | |||
| NAN Change of Director's Interest Notice | |||
| 06/03/18 | |||
| NAN Appendix 3B | |||
| 06/03/18 | |||
| NAN 2018 Half Year Results Investor Presentation | |||
| 26/02/18 | PRICE SENSITIVE | ||
| NAN Appendix 4D and Half Year Report | |||
| 23/02/18 | PRICE SENSITIVE | ||
